In short
BAY 3670549 is an investigational substance being studied for the treatment of atrial fibrillation (AF), a common heart rhythm disorder. One Phase 2 clinical trial is currently authorised in the EU, planning to enrol 132 participants. The trial will test whether BAY 3670549 can help restore a normal heart rhythm (sinus rhythm) in patients with AF.
Key points
- BAY 3670549 is an investigational substance with no marketing authorisation.
- It is being studied in a Phase 2 trial for atrial fibrillation.
- The trial plans to enrol 132 participants.
- The trial is currently authorised but not yet recruiting.
- The main measure is conversion from atrial fibrillation to sinus rhythm within 3 hours.
- BAY 3670549 is given as an infusion in this trial.
What is BAY 3670549?
BAY 3670549 is an investigational substance being developed for the treatment of atrial fibrillation (AF), a condition where the heart beats irregularly and often too fast. It is not yet an authorised medicine; the available registry records show no marketing authorisation for this substance. The substance is given by infusion in the clinical trial setting.
How does BAY 3670549 work?
The registry data provided do not describe the mechanism of action of BAY 3670549. The trial is designed to test whether the substance can restore a normal heart rhythm, known as sinus rhythm, in patients with atrial fibrillation. No further information on how the substance acts in the body is available from the provided sources.
Which conditions is it studied for?
- Atrial fibrillation — a common heart rhythm disorder in which the upper chambers of the heart beat irregularly. The trial tests whether BAY 3670549 can convert this rhythm back to a normal sinus rhythm.
How is BAY 3670549 given?
In the clinical trial, BAY 3670549 is administered as an infusion. The trial record also lists a placebo infusion as a comparison arm. No oral or other formulations are mentioned in the provided data.
What do the clinical trials show?
One Phase 2 trial of BAY 3670549 is authorised in the EU. It is an interventional study planning to enrol 132 participants with atrial fibrillation. The trial is currently authorised but not yet recruiting, according to the registry record.
The primary outcome measure is the proportion of participants who convert from atrial fibrillation to sinus rhythm, sustained for at least one minute, within three hours after the start of study intervention, and before any rescue therapy or standard of care cardioversion is used. The trial compares BAY 3670549 infusion against a placebo infusion.
What side effects are known?
No information on side effects is available from the provided sources.